{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T21:11:23Z","timestamp":1760735483272,"version":"build-2065373602"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,4]],"date-time":"2021-09-04T00:00:00Z","timestamp":1630713600000},"content-version":"am","delay-in-days":338,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100003323","name":"Agence Nationale de Recherches sur le Sida et les H\u00e9patites Virales","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003323","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.ejca.2020.07.033","type":"journal-article","created":{"date-parts":[[2020,9,4]],"date-time":"2020-09-04T08:10:55Z","timestamp":1599207055000},"page":"189-192","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Favorable outcome of HIV-associated Burkitt lymphoma in the modern combined antiretroviral therapy era"],"prefix":"10.1016","volume":"138","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9065-0477","authenticated-orcid":false,"given":"Lo\u00efc","family":"Vasseur","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Prevot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Mounier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominique","family":"Costagliola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4364-7173","authenticated-orcid":false,"given":"Caroline","family":"Besson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2020.07.033_bib1","doi-asserted-by":"crossref","first-page":"e240","DOI":"10.1016\/S2352-3018(18)30360-6","article-title":"Association of immunosuppression and HIV viraemia with non-Hodgkin lymphoma risk overall and by subtype in people living with HIV in Canada and the USA: a multicentre cohort study","volume":"6","author":"Hern\u00e1ndez-Ram\u00edrez","year":"2019","journal-title":"Lancet HIV"},{"key":"10.1016\/j.ejca.2020.07.033_bib2","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1182\/blood-2015-01-623900","article-title":"Amc 048: modified CODOX-M\/IVAC-rituximab is safe and effective for HIV-associated Burkitt lymphoma","volume":"126","author":"Noy","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2020.07.033_bib3","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.3109\/10428194.2013.878933","article-title":"Dose-intensive chemotherapy including rituximab is highly effective but toxic in human immunodeficiency virus-infected patients with Burkitt lymphoma\/leukemia: parallel study of 81 patients","volume":"55","author":"Xicoy","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ejca.2020.07.033_bib4","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/hon.2437_122","article-title":"Risk-Adapted therapy IN adults with burkitt lymphoma: updated results of a multicenter prospective phase ii study of DA-EPOCH-R","volume":"35","author":"Dunleavy","year":"2017","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.ejca.2020.07.033_bib5","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s00277-013-1771-8","article-title":"Burkitt lymphomas failing dose-adjusted R-EPOCH (DA-R-EPOCH)","volume":"93","author":"Aurer","year":"2014","journal-title":"Ann Hematol"},{"key":"10.1016\/j.ejca.2020.07.033_bib6","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1016\/S0140-6736(15)01317-3","article-title":"Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Ribrag","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2020.07.033_bib7","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1097\/QAD.0000000000001652","article-title":"Outcomes for HIV-associated diffuse large B-cell lymphoma in the modern combined antiretroviral therapy era","volume":"31","author":"Besson","year":"2017","journal-title":"AIDS"},{"key":"10.1016\/j.ejca.2020.07.033_bib8","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1093\/cid\/civ627","article-title":"High risk features contrast with favorable outcomes in HIV-associated Hodgkin lymphoma in the modern cART era, ANRS CO16 Lymphovir cohort","volume":"61","author":"Besson","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ejca.2020.07.033_bib9","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1111\/bjh.13221","article-title":"Survival of AIDS-related diffuse large B-cell lymphoma, Burkitt lymphoma, and plasmablastic lymphoma in the German HIV Lymphoma Cohort","volume":"168","author":"Schommers","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejca.2020.07.033_bib10","doi-asserted-by":"crossref","first-page":"857","DOI":"10.3324\/haematol.2017.180893","article-title":"Incidence and risk factors for relapses in HIV-associated non-Hodgkin lymphoma as observed in the German HIV-related lymphoma cohort study","volume":"103","author":"Schommers","year":"2018","journal-title":"Haematologica"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804920304330?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804920304330?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:29:18Z","timestamp":1760732958000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804920304330"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":10,"alternative-id":["S0959804920304330"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2020.07.033","relation":{},"ISSN":["0959-8049"],"issn-type":[{"type":"print","value":"0959-8049"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Favorable outcome of HIV-associated Burkitt lymphoma in the modern combined antiretroviral therapy era","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2020.07.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}